Non-Hodgkin Lymphoma Pipeline, Clinical Trials, FDA Approvals and Companies 2024 (Updated)

DelveInsight's, "Non-Hodgkin Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 200+ Non-Hodgkin Lymphoma companies and 220+ pipeline drugs in the Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report
• DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working to develop 220+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
• The leading Non-Hodgkin Lymphoma Companies working in the market include Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
• Promising Non-Hodgkin Lymphoma Pipeline Therapies in the various stages of development include Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.
• April 2024:- AbbVie- Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma. B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.
• April 2024:- Sichuan Baili Pharmaceutical Co., Ltd.- An Open, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Quad-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin's Lymphoma, Relapsed or Refractory Acute Lymphoblastic Leukemia, and Refractory or Metastatic Solid Tumors.

Request a sample and discover the recent advances in Non-Hodgkin Lymphoma Treatment Drugs @ Non-Hodgkin Lymphoma Pipeline Outlook Report- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Non-Hodgkin Lymphoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Non-Hodgkin Lymphoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Non-Hodgkin Lymphoma clinical trial landscape.

Non-Hodgkin Lymphoma Overview
Non-Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, usually found in the lymph nodes. NHL is not a single disease but rather a group of several closely related cancers, called lymphoid neoplasms. The most recent 2016 revision of the World Health Organization's classification of lymphoid neoplasms estimates that there are at least 86 types of NHL.

Find out more about Non-Hodgkin Lymphoma Treatment Landscape @ Drugs for Non-Hodgkin Lymphoma Treatment- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non-Hodgkin Lymphoma Emerging Drugs Profile
• Mosunetuzumab: Hoffmann-la Roche
• Tisagenlecleucel: Novartis
• Capivasertib: AstraZeneca
• BI-1206: BioInvent
• HMPL-760: Hutchmed

Non-Hodgkin Lymphoma Pipeline Therapeutics Assessment
There are approx. 200+ key Non-Hodgkin Lymphoma companies which are developing the Non-Hodgkin Lymphoma therapies. The Non-Hodgkin Lymphoma Companies which have their Non-Hodgkin Lymphoma drug candidates in the most advanced stage, i.e. phase III include, Hoffmann-la Roche.

DelveInsight's Non-Hodgkin Lymphoma pipeline report covers around 220+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Non-Hodgkin Lymphoma Pipeline Therapies @ Non-Hodgkin Lymphoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Non-Hodgkin Lymphoma Pipeline Report
• Coverage- Global
• Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
• Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.

Dive deep into rich insights for new drugs for Non-Hodgkin Lymphoma treatment, Visit @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Non-Hodgkin Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Hodgkin Lymphoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Tisagenlecleucel: Novartis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Capivasertib: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. BI-1206: BioInvent
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. HMPL-760: Hutchmed
18. Drug profiles in the detailed report…..
19. Preclinical Stage Products
20. Product Name: Company Name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Hodgkin Lymphoma Key Companies
24. Non-Hodgkin Lymphoma Key Products
25. Non-Hodgkin Lymphoma- Unmet Needs
26. Non-Hodgkin Lymphoma- Market Drivers and Barriers
27. Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
28. Non-Hodgkin Lymphoma Analyst Views
29. Non-Hodgkin Lymphoma Key Companies
30. Appendix

For further information on the Non-Hodgkin Lymphoma pipeline therapeutics, reach out to Non-Hodgkin Lymphoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Published Links-
https://www.hoyolab.com/article/27093025
https://www.kfz-betrieb.vogel.de/community/user/ybhardwaj
https://pad.funkwhale.audio/s/z1sjb2E6Z
https://swaay.com/u/daviddollareusa/about/
https://www.bestadsontv.com/profile/462518/Denny-Dones
https://manybooks.net/user/denny-dones
https://topbazz.com/germanydennydones
https://wibki.com/dennydones1
https://onlineghibli.com/tavern/members.php?mode=profile&userid=12548&boardid=1
https://www.undrtone.com/germanydennydon
https://solo.to/germanydennydones
https://app.geniusu.com/users/2455075
https://forum.alidropship.com/members/germanydennydones.50354/#about
https://pantip.com/profile/7306022#topics
https://pubhtml5.com/homepage/npvs/preview
https://doodleordie.com/profile/germanydennydones
https://www.rafabasa.com/author/germanydennydones/
https://www.tabletennisdaily.com/forum/members/germanydennydones.122613/#about
https://nhattao.com/members/user6331540.6331540/
https://thelittlenet.com/dennydonesgerman
http://demo.advised360.com/read-blog/154799
https://thehealthbridges.com/read-blog/19127
https://app.talkshoe.com/user/joneswilliam/about#google_vignette
https://www.vaca-ps.org/blogs/142022/The-Evolving-Landscape-of-Healthcare-Business-Consulting-Services
https://www.anobii.com/en/01d38d0b9694756e64/profile/activity
https://myanimelist.net/profile/dennydonesgerman
https://forum.pivx.org/threads/healthcare-business-consulting-services-navigating-complexity-in-modern-healthcare.2035/
https://pubhtml5.com/homepage/npvs/
https://b31.org.uk/author/anniesmith9/
https://fairygodboss.com/users/profile/Ix-vMa09gj/Annie-Smith
https://forum.completefrance.com/index.php?/topic/71194-key-areas-of-focus-in-healthcare-consulting-services/
https://educatorpages.com/site/kelleadvin/pages/blog?
https://offgridworld.com/author/anniejones9/
https://www.openhumans.org/member/me/
https://findpenguins.com/5zphebtv0zouo
http://jobs.emiogp.com/author/williamsmith9/
https://www.shippingexplorer.net/en/user/williamsmith9/88249
https://wakelet.com/@DennyDones813
https://startupxplore.com/en/person/denny-dones
https://www.nfpjobs.com.au/employers/1939365-delveinsight
https://community.hodinkee.com/members/dennydoness
https://jobs.mikeroweworks.org/employers/1930150-delveinsight
https://www.social-vape.com/read-blog/132516
https://codex.core77.com/users/dennydones9
https://www.newjerseyhunter.com/members/dennydones1.84566/#about
https://au.blurb.com/user/dennydones9?profile_preview=true
https://trabajo.merca20.com/author/kelleadvin/
https://www.atlasobscura.com/users/dennydones1
https://www.mixcloud.com/dennydones1/
https://www.designspiration.com/ybhardwaj/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.